Worsening congestive heart failure requiring hospitalization or occurring in-hospital was nonsignificantly higher in the bisoprolol group (n=63 vs
Heart failure β-blocker Prognosis Comorbidities COPD Diabetes Atrial fibrillation Erectile dysfunction Peripheral arterial disease 1
Conclusions —BHR and HRC are significantly related to prognosis in heart failure
In this study, the risk of heart failure, including HFpEF, became significantly lower at around 2,500 steps per day
Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients
They argue
2,3 Meta-analyses of placebo-controlled trials of β-blockers have suggested an
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
Background To further evaluate the mechanism of β-blocker–induced benefits in heart failure, the relationships between bisoprolol-induced hemodynamic effects and Bristow MR, Cohn
The U
To discuss the use of oral bisoprolol in patients with chronic heart failure (CHF) associated with systolic dysfunction
Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients
to download this conveniently visit: These trials included the Metoprolol in Dilated Cardiomyopathy (MDC) 93,94 study, the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF), 6,9 the Cardiac Insufficiency Bisoprolol Studies (CIBIS I and II), 4,5 the Australia, New Zealand, and United States Carvedilol Clinical Trial 8 program, the Carvedilol Prospective This study aimed to analyze the degree of concordance between targeted (CIBIS II) and achieved doses of bisoprolol in a group of patients with stable heart failure on conventional treatment
Improvement in survival on b-blockade remains
1,2 But does it matter which intervention is given first? There are 2 primary
5 mg to 3
Beta-blockers have become one of the mainstays of chronic heart failure (CHF) therapy since they improve both morbidity and mortality in patients with reduced ejection fraction [1,2,3,4,5,6,7,8]
It is taken by mouth
4–6The Cardiac Insufficiency Bisoprolol Study (CIBIS) studied bisoprolol, a highly selective antagonist of β 1 adrenoceptors, which are The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
In a study of 31 325 Medicare patients with heart failure published by the instrument developers, 17 the MCIDs for To investigate this last issue, the BISOCOR study, a prospective, observational, multicenter study, was designed to assess the use of a bisoprolol regimen with dose increments based on the recommendations of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) 14 in a large group of patients with heart failure who were followed in However, as has been shown for left heart failure, chronic adrenergic overstimulation might be detrimental in the long run
INTRODUCTION
Beta-blockers have been shown to be of clinical benefit in patients with chronic heart failure (Greenberg 2004)
However, it is disputed whether beta-blockers exert a class effect or whether there are differences in efficacy between agents